Showing results (31-40 of 192) with videos related to

Sort By:
Pageof 20
Therapeutic Advances in Hematology|April 5, 2013
Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletionVu H Duong, Rami S Komrokji, Alan F List
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivativesHerson I Quiñones, Alan F List, Eugene W Gerner
Current Hematologic Malignancy Reports|March 29, 2011
Management of lower-risk myelodysplastic syndromes: the art and evidenceRami S Komrokji, Mikkael A Sekeres, Alan F List
Expert Opinion on Pharmacotherapy|August 1, 2014
Update on the pharmacotherapy for myelodysplastic syndromesVu H Duong, Rami S Komrokji, Alan F List
Cancer Control : Journal of the Moffitt Cancer Center|October 9, 2012
Advances in the management of myelofibrosisRami S Komrokji, Srdan Verstovsek, Eric Padron, et al.
Cancer Control : Journal of the Moffitt Cancer Center|January 24, 2007
Lenalidomide: targeted anemia therapy for myelodysplastic syndromesAlan F List, Amanda F Baker, Sylvan Green, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2013
Prognostic factors and risk models in myelodysplastic syndromesRami S Komrokji, Eric Padron, Jeffrey E Lancet, et al.
Expert Opinion on Emerging Drugs|November 21, 2012
Emerging immunosuppressive drugs in myelodysplastic syndromesPearlie K Epling-Burnette, Jessica McDaniel, Sheng Wei, et al.
Best Practice & Research. Clinical Haematology|February 11, 2014
Deletion 5q MDS: molecular and therapeutic implicationsRami S Komrokji, Eric Padron, Benjamin L Ebert, et al.
Leukemia & Lymphoma|December 15, 2016
The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implicationsLing Zhang, Kathy L McGraw, David A Sallman, et al.
Pageof 20